Related Experiment Video

Updated: Dec 12, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

COVID-19 and immunosuppressive therapy in dermatology

Robert A Schwartz1, Swetalina Pradhan2, Dedee F Murrell3

  • 1Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Dermatologic Therapy
|August 10, 2020
PubMed

Insights

Managing skin conditions during the COVID-19 pandemic requires careful consideration of immunosuppressants. This study addresses treatment strategies for immunocompromised patients with skin diseases, considering the novel coronavirus

Area of Science:

  • Immunology
  • Dermatology
  • Infectious Diseases

Background:

  • The COVID-19 pandemic presents unique challenges for managing patients with skin diseases requiring immunosuppressive therapy.
  • Concerns exist regarding the potential for immunosuppressants to exacerbate COVID-19 severity and outcomes.
  • Incomplete understanding of the immune response to COVID-19 and post-infection immunity complicates treatment decisions.

Purpose of the Study:

  • To outline management strategies for skin diseases in immunocompromised patients during the COVID-19 pandemic.
  • To address the risks associated with systemic immunosuppressants in the context of COVID-19.
  • To provide guidance considering the evolving knowledge of SARS-CoV-2 and its immunological effects.

Main Methods:

  • Review of current literature on COVID-19, immunosuppression, and dermatology.
  • Analysis of clinical considerations for managing skin conditions in vulnerable populations.
  • Discussion of risk-benefit assessments for immunosuppressive therapies.

Main Results:

  • Identification of key challenges in balancing dermatological care with COVID-19 risks.
  • Highlighting the need for individualized treatment plans based on patient immunity and disease severity.
  • Emphasizing cautious use of immunosuppressants and monitoring for COVID-19.

Conclusions:

  • Effective management of skin diseases in immunocompromised individuals during the pandemic necessitates a cautious and informed approach to immunosuppression.
  • Further research is needed to fully understand the long-term immunological consequences of COVID-19 and its interaction with immunosuppressive therapies.
  • Close collaboration between dermatologists and infectious disease specialists is crucial for optimal patient care.

Keywords:
COVID 19dermatologyimmunosuppressive therapy

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.6K
Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis11:28

Imaging CD4 T Cell Interstitial Migration in the Inflamed Dermis

Published on: March 25, 2016

11.1K

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
669
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
360
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
325